| Entry |
|
|---|
| Name |
Irinotecan hydrochloride (USP);
Irinotecan hydrochloride hydrate (JP18);
Irinotecan hydrochloride trihydrate;
CPT 11;
CPT-11;
Campto (TN);
Camptosar (TN);
Onivyde (TN) |
|---|
| Product |
|
|---|
| Generic |
IRINOTECAN HYDROCHLOIDE (BluePoint Laboratories), IRINOTECAN HYDROCHLOIDE (Gland Pharma Limited), IRINOTECAN HYDROCHLOIDE (Xiromed LLC), IRINOTECAN HYDROCHLORIDE (Actavis Pharma), IRINOTECAN HYDROCHLORIDE (Apotex Corp.), IRINOTECAN HYDROCHLORIDE (Apotex Corp.), IRINOTECAN HYDROCHLORIDE (Armas Pharmaceuticals), IRINOTECAN HYDROCHLORIDE (Armas Pharmaceuticals), IRINOTECAN HYDROCHLORIDE (Armas Pharmaceuticals), IRINOTECAN HYDROCHLORIDE (Eugia US LLC), IRINOTECAN HYDROCHLORIDE (Fresenius Kabi USA), IRINOTECAN HYDROCHLORIDE (Hikma Pharmaceuticals USA), IRINOTECAN HYDROCHLORIDE (Hikma Pharmaceuticals USA), IRINOTECAN HYDROCHLORIDE (Hospira), IRINOTECAN HYDROCHLORIDE (Ingenus Pharmaceuticals), IRINOTECAN HYDROCHLORIDE (Northstar Rx LLC), IRINOTECAN HYDROCHLORIDE (Qilu Pharmaceutical), IRINOTECAN HYDROCHLORIDE (Sagent Pharmaceuticals) |
|---|
| Formula |
C33H38N4O6. 3H2O. HCl
|
|---|
| Exact mass |
676.2875
|
|---|
| Mol weight |
677.18
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
|
|---|
| Remark |
| Therapeutic category: | 4240 |
| Product (DG00726): | D01061<JP/US> |
|
|---|
| Efficacy |
Antineoplastic, Topoisomerase I inhibitor |
|---|
| Disease |
Adenocarcinoma of the pancreas [DS: H00019] Carcinoma of the colon or rectum [DS: H00020] |
|---|
| Comment |
Camptothecin [CPD: C01897] derivative
Irinotecan forms cleavable complex with DNA and inhibit DNA synthesis.
Active form of prodrug: SN-38 [CPD: C11173]
|
|---|
| Target |
|
|---|
| Metabolism |
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07042 | Antineoplastics - agents from natural products |
|
|---|
| Other map |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01C PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS
L01CE Topoisomerase 1 (TOP1) inhibitors
L01CE02 Irinotecan
D01061 Irinotecan hydrochloride (USP) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Topoisomerase Inhibitors
Irinotecan
D01061 Irinotecan hydrochloride (USP)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
424 Plant extract preparations
4240 Plant extract preparations
D01061 Irinotecan hydrochloride (USP); Irinotecan hydrochloride hydrate (JP18)
Drug groups [BR:br08330]
Antineoplastic
DG01529 Topoisomerase inhibitor
DG01526 Topoisomerase I inhibitor
DG00726 Irinotecan
D01061 Irinotecan hydrochloride
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00726 Irinotecan
D01061 Irinotecan hydrochloride
DG02970 CES substrate
DG00726 Irinotecan
D01061 Irinotecan hydrochloride
DG02924 UGT substrate
DG03183 UGT1A1 substrate
DG00726 Irinotecan
D01061 Irinotecan hydrochloride
Target-based classification of drugs [BR:br08310]
Enzymes
Isomerases (EC5)
DNA topoisomerase
TOP1
D01061 Irinotecan hydrochloride (USP) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D01061 Irinotecan hydrochloride
D01061 Irinotecan hydrochloride injection
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D01061
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D01061
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D01061
Drug groups [BR:br08330]
Antineoplastic
DG01529 Topoisomerase inhibitor
DG01526 Topoisomerase I inhibitor
DG00726 Irinotecan
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00726 Irinotecan
DG02970 CES substrate
DG00726 Irinotecan
DG02924 UGT substrate
DG03183 UGT1A1 substrate
DG00726 Irinotecan
Prodrugs [br08324.html]
DG00726
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 47
1 X Cl 6.3178 -11.7757
2 O0 O 10.5410 -11.7757
3 C8y C 12.1100 -7.2100
4 C8x C 12.1100 -8.6100
5 C8x C 13.3224 -9.3100
6 C8y C 14.5349 -8.6100
7 C8y C 14.5349 -7.2100
8 C8x C 13.3224 -6.5100
9 N5x N 15.7473 -9.3100
10 C8y C 16.9597 -8.6100
11 C8y C 16.9597 -7.2100
12 C8y C 15.7473 -6.5100
13 O7a O 10.8976 -6.5100
14 C7a C 9.6851 -7.2100
15 O6a O 9.6851 -8.6100
16 N1y N 8.4540 -6.4990
17 C1x C 8.4543 -5.1101
18 C1x C 7.2420 -4.4098
19 C1y C 6.0294 -5.1095
20 C1x C 6.0291 -6.4984
21 C1x C 7.2414 -7.1987
22 N1y N 4.8103 -4.4053
23 C1x C 4.8107 -3.0101
24 C1x C 3.5985 -2.3098
25 C1x C 2.3859 -3.0094
26 C1x C 2.3854 -4.4045
27 C1x C 3.5977 -5.1049
28 C8y C 18.2912 -9.0426
29 N4y N 19.1141 -7.9100
30 C1x C 18.2912 -6.7774
31 C8y C 20.5100 -7.9100
32 C8y C 21.2100 -9.1224
33 C8y C 20.5196 -10.3179
34 C8x C 19.1103 -10.3180
35 C1z C 21.2195 -11.5304
36 C7x C 22.6195 -11.5306
37 O7x O 23.3099 -10.3351
38 C1x C 22.6100 -9.1226
39 O5x O 21.2100 -6.6976
40 O6a O 23.3254 -12.7534
41 C1b C 15.7473 -5.1100
42 C1a C 14.5369 -4.4112
43 C1b C 19.8195 -11.5304
44 O1a O 21.2195 -12.9500
45 C1a C 19.1121 -12.7636
46 O0 O 10.5410 -11.7757
47 O0 O 10.5410 -11.7757
BOND 49
1 3 4 2
2 4 5 1
3 5 6 2
4 6 7 1
5 7 8 2
6 3 8 1
7 6 9 1
8 9 10 2
9 10 11 1
10 11 12 2
11 7 12 1
12 3 13 1
13 13 14 1
14 14 15 2
15 14 16 1
16 16 17 1
17 17 18 1
18 18 19 1
19 19 20 1
20 20 21 1
21 16 21 1
22 19 22 1
23 22 23 1
24 23 24 1
25 24 25 1
26 25 26 1
27 26 27 1
28 22 27 1
29 10 28 1
30 28 29 1
31 29 30 1
32 11 30 1
33 29 31 1
34 31 32 1
35 32 33 2
36 33 34 1
37 33 35 1
38 35 36 1
39 36 37 1
40 37 38 1
41 32 38 1
42 34 28 2
43 31 39 2
44 36 40 2
45 12 41 1
46 41 42 1
47 35 43 1 #Down
48 35 44 1 #Up
49 43 45 1
BRACKET 1 8.6800 -12.7400 8.6800 -10.6400
1 11.0600 -10.6400 11.0600 -12.7400
1 3
ORIGINAL 1 2
REPEAT 1 46 47
|
|---|
